SPI-2012, Spectrum's third biological drug, is a long-acting Granulocyte- Colony Stimulating Factor (G-CSF) that utilizes Hanmi Pharmaceuticals proprietary platform technology, LAPSCOVERY™.
G-CSF stimulates proliferation of granulocyte progenitors and subsequent production of neutrophils in the bone marrow. A recombinant form of G-CSF is used in appropriate cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens to be given at full-dose and on schedule. Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells, making patients prone to infections, hospitalizations, and interruption of additional chemotherapy treatments.
Route of Administration
Mode of ActionBinds to the G-CSF receptor expressed on granulocyte progenitors and stimulates their proliferation and subsequent maturation to functionally active neutrophils.
SPI-2012 could have potential advantages for more rapid and profound granulocyte recovery in patients with chemotherapy induced neutropenia, a multibillion dollar worldwide market
If SPI-2012 is ultimately commercialized, Spectrum shall own worldwide rights except for Korea, China, and Japan.
SPI-2012 Mechanism of Action